Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Severe sulfonylurea-induced hypoglycemia (SH) remains a life-threatening and under-reported condition. We investigated the incidence of SH and clinical characteristics of patients with type 2 diabetes mellitus (T2DM) to demonstrate typical risk constellations. METHODS: In a prospective population-based observational study, all consecutive cases of SH in the period 2000 - 2009 in a German area with 200,000 inhabitants were registered. Severe hypoglycemia was defined as a symptomatic event requiring treatment with intravenous glucose and was confirmed by a blood glucose measurement of < 50 mg/dl. RESULTS: A mean incidence of seven episodes of SH per year and 100,000 inhabitants was registered. The 139 hypoglycemic individuals had been treated with glimepiride (n = 98), glibenclamide (n = 40) or gliquidone (n = 1). No preparation showed a constant dose-effect relationship, SH occurring within a wide dose range. The patients were characterized as follows: age 77.5 + or - 9.4 years, duration of diabetes 11 + or - 7 years, body mass index 26.3 + or - 4.9 kg/m(2), HbA1c 6.6 + or - 1.3%, creatinine clearance 46 + or - 24 ml/min with renal insufficiency in 73% and co-medication 7 + or - 3 drugs. Two-thirds of all subjects lived independently at home whereas a third were cared for by a home nursing service or received care in nursing homes. In all, 30% had participated in diabetes education programs. In 31%, systematic blood glucose monitoring was performed. CONCLUSIONS: Uncritical prescription of sulfonylureas neglecting crucial contraindications - particularly renal insufficiency - and deficiencies of diabetes care contributed substantially to the risk of SH in the mainly geriatric patients. There is a need for alternative therapeutic concepts that minimize the risk of hypoglycemia in geriatric patients with T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 2×
“Recent results from large interventional studies (ACCORD, ADVANCE, VDAT) [2,24,25] for the prevention of vascular complications and data from observational studies [26] revealed that tight glycemic control in patients with T2DM is of limited value and may even increase cardiovascular and all-cause mortality.”
BackgroundResultDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“As DPP-4 inhibitors and GLP-1 agonists stimulate insulin secretion from b cells in the pancreas in response to food intake in a glucose-dependent manner, their risk of hypoglycemia is low [34].”
BackgroundStandards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus
Whitmer, R. A. (2009) · JAMA · doi:10.1001/jama.2009.460 · Cited by 1,128 · cited 1×
“Nowadays, severe hypoglycemia in patients with T2DM is regarded as a predictor for an increased cardiovascular and general mortality [2] and also as a possible substantial risk factor for dementia [3].”
BackgroundThe influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“Furthermore, patients with T2DM exposed to SUs had a significantly increased risk of cancer and cancer-related mortality compared with those exposed to metformin [6,7].”
BackgroundNew Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996 · cited 1×
“Furthermore, patients with T2DM exposed to SUs had a significantly increased risk of cancer and cancer-related mortality compared with those exposed to metformin [6,7].”
BackgroundSurvival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
Currie, C. J., Peters, J. R., Tynan, A., Evans, M., Heine, R. J., Bracco, O. L., Zagar, T., & Poole, C. D. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61969-3 · Cited by 874 · cited 1×
“Recent results from large interventional studies (ACCORD, ADVANCE, VDAT) [2,24,25] for the prevention of vascular complications and data from observational studies [26] revealed that tight glycemic control in patients with T2DM is of limited value and may even increase cardiovascular and all-cause mortality.”
Frequency of Severe Hypoglycemia Requiring Emergency Treatment in Type 1 and Type 2 Diabetes
Leese, G. P., Wang, J., Broomhall, J., Kelly, P., Marsden, A., Morrison, W., Frier, B. M., Morris, A. D., & For the DARTS/MEMO Collaboration (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1176 · Cited by 559
Hypoglycaemia in Type 2 diabetes
Amiel, S. A., Dixon, T., Mann, R., & Jameson, K. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02341.x · Cited by 472 · cited 1×
“Unchanged, the decisive risk factors for SH are still represented by advanced age, long diabetes duration, extensive comorbidity with higher degrees of renal insufficiency, polypharmacy and the use of long- versus short-acting preparations [30].”
BackgroundTzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., et al. (2009) · BMJ · doi:10.1136/bmj.b4731 · Cited by 444 · cited 1×
“Large retrospective observational studies suggest that relative to metformin, SUs are associated with an excess risk of all-cause mortality, myocardial infarction and congestive heart failure [4,5].”
BackgroundHypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes
Bremer, J. P., Jauch-Chara, K., Hallschmid, M., Schmid, S., & Schultes, B. (2009) · Diabetes Care · doi:10.2337/dc09-0114 · Cited by 298 · cited 1×
“Recent data indicated marked subjective unawareness of hypoglycemia with reduced autonomic and neuroglycopenic symptoms in older type 2 diabetic patients who did not depend on altered neuroendocrine counter-regulation and may contribute to the increased probability of severe hypoglycemia [20].”
BackgroundEvans, J. M. M., Ogston, S. A., Emslie-Smith, A., & Morris, A. D. (2006) · Diabetologia · doi:10.1007/s00125-006-0176-9 · Cited by 293 · cited 1×
“Large retrospective observational studies suggest that relative to metformin, SUs are associated with an excess risk of all-cause mortality, myocardial infarction and congestive heart failure [4,5].”
BackgroundHolstein, A., Plaschke, A., & Egberts, E. (2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.235 · Cited by 264 · cited 2×
“Although it has been postulated that glimepiride differs from glibenclamide in its receptor kinetics and pharmacokinetics with a considerably lower binding affinity to the b-cell SU-receptor with a high exchange rate, both drugs carry a high risk of severe sulfonylurea-induced hypoglycemia (SH) in geriatric patients […”
BackgroundSelf-citation
Cited by
Barnett, A. H., Huisman, H., Jones, R., von Eynatten, M., Patel, S., & Woerle, H.-J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61500-7 · Cited by 183
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
Ahren, B. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33934 · Cited by 148
“One such risk factor for hypoglycemia is old age.(36) Increased risk for hypoglycemia in elderly subjects may be due to increased sensitivity to medication and compromised counterregulation.”
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
Scheen, A. J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.777428 · Cited by 91
Nursing home patients with diabetes: prevalence, drug treatment and glycemic control
Andreassen, L. M., Sandberg, S., Kristensen, G. B. B., Sølvik, U. Ø., & Kjome, R. L. S. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.012 · Cited by 60
“[16] Holstein A, Hammer C, Hahn M, Kulamadayil NS, Kovacs P.”
BackgroundBruderer, S. G., Bodmer, M., Jick, S. S., Bader, G., Schlienger, R. G., & Meier, C. R. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12282 · Cited by 53
“Renal failure was associated with an increased risk for severe hypoglycaemia in the overall case–control population and in non-insulin users compared with the respective non-exposed patients in accordance with the results from the follow-up study and previously reported data [4,32].”
Result
Metadata
- Authors
- Holstein, A., Hammer, C., Hahn, M., Kulamadayil, N.-S.-A., & Kovacs, P.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa Healthcare
- Published
- 2010-06-16
- Volume
- 9
- Issue
- 5
- Pages
- 675-681
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2103157177
- Cited by
- 74
- References
- 13
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.